Regeneron Nabs BARDA Ebola Antibodies Cocktail Deal
This article was originally published in Scrip
Executive Summary
The U.S. Biomedical Advanced Research and Development Authority (BARDA) awarded Regeneron Pharmaceuticals Inc. $17m to develop, test and manufacture a monoclonal antibody (mAb) therapy to treat Ebola under an agreement in which the company could garner an additional $21m to test the product in a Phase I trial.